Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Preliminary studies suggested that delta-9-tetrahydrocannabinol (THC), the major psychoactive ingredient of Cannabis sativa L., might be effective in the treatment of Tourette syndrome (TS). This study was performed to investigate for the first time under controlled conditions, over a longer-term treatment period, whether THC is effective and safe in reducing tics in TS. Method In this randomized, double-blind, placebo-controlled study, 24 patients with TS, according to DSM-III-R criteria, were treated over a 6-week period with up to 10 mg/day of THC. Tics were rated at 6 visits (visit 1, baseline; visits 2-4, during treatment period; visits 5-6, after withdrawal of medication) using the Tourette Syndrome Clinical Global Impressions scale (TS-CGI), the Shapiro Tourette-Syndrome Severity Scale (STSSS), the Yale Global Tic Severity Scale (YGTSS), the self-rated Tourette Syndrome Symptom List (TSSL), and a videotape-based rating scale. Results Seven patients dropped out of the study or had to be excluded, but only 1 due to side effects. Using the TS-CGI, STSSS, YGTSS, and video rating scale, we found a significant difference (p Conclusion Our results provide more evidence that THC is effective and safe in the treatment of tics. It, therefore, can be hypothesized that the central cannabinoid receptor system might play a role in TS pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., & Bonner, T. I. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5780 · Cited by 1,064
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Tourette syndrome, associated conditions and the complexities of treatment
Robertson, M. M. (2000) · Brain · doi:10.1093/brain/123.3.425 · Cited by 704
CB1 Cannabinoid Receptor Inhibits Synaptic Release of Glutamate in Rat Dorsolateral Striatum
Gerdeman, G., & Lovinger, D. M. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.1.468 · Cited by 433
A Functional Neuroanatomy of Tics in Tourette Syndrome
Stern, E., Silbersweig, D. A., Chee, K.-Y., Holmes, A., Robertson, M. M., Trimble, M., Frith, C. D., Frackowiak, R. S. J., & Dolan, R. J. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.741 · Cited by 333
Cited by
Items 101–200 of 272
The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation
Graczyk, M., Lewandowska, A. A., & Dzierżanowski, T. (2021) · Molecules · doi:10.3390/molecules26154551 · Cited by 44
Clinical Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v04n01_03 · Cited by 44
“During a study on the efficacy of dronabinol (THC) in 24 patients with Tourette syndrome who received up to 10 mg THC daily for 6 weeks, no detrimental effects were seen on neuropsychological performance (learning, recall of word lists, visual memory, divided attention) (Müller-Vahl et al. 2003a).”
BackgroundNondopaminergic Neurotransmission in the Pathophysiology of Tourette Syndrome
Udvardi, P. T., Nespoli, E., Rizzo, F. R., Hengerer, B., & Ludolph, A. G. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00004-4 · Cited by 41
Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome
Mosley, P. E., Webb, L., Suraev, A. S., Hingston, L., Turnbull, T. A., Foster, K. A., Ballard, E. L., Gomes, L., Mohan, A., Sachdev, P. S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300012 · Cited by 38
Premonitory Urge and Tic Severity, Comorbidities, and Quality of Life in Chronic Tic Disorders
Brandt, V. C., Essing, J., Jakubovski, E., & Müller‐Vahl, K. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13742 · Cited by 37
Roessner, V., Banaschewski, T., & Rothenberger, A. (2004) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917.32.4.245 · Cited by 38
Single center experience with medical cannabis in Gilles de la Tourette syndrome
Thaler, A., Arad, S., Schleider, L. B., Knaani, J., Taichman, T., Giladi, N., & Gurevich, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.004 · Cited by 35
A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome
Abi‐Jaoude, E., Bhikram, T., Parveen, F., Levenbach, J., Lafrenière‐Roula, M., & Sandor, P. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0091 · Cited by 38
Poulet, E., Brunelin, J., Kallel, L., d’Amato, T., & Saoud, M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060868 · Cited by 36
The influence of different food and drink on tics in Tourette syndrome
Müller‐Vahl, K., Buddensiek, N., Geomelas, M., & Emrich, H. M. (2008) · Acta Paediatrica · doi:10.1111/j.1651-2227.2008.00675.x · Cited by 34
Self-citationCannabis Improves Obsessive-Compulsive Disorder—Case Report and Review of the Literature
Szejko, N., Fremer, C., & Müller‐Vahl, K. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00681 · Cited by 33
Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 39
“Recent reviews [91, 99–101] identified only two RCTs of CBP for treatment of with TS; a double-blind placebo-controlled cross-over single-dose trial [102], and a randomised, double-blind placebo-controlled 6-week trial [93].”
BackgroundHupli, A. (2018) · Medical Cannabis and Cannabinoids · doi:10.1159/000495307 · Cited by 58
Survey on the Medical Use of Cannabis and THC in Germany
Grotenhermen, F., & Schnelle, M. (2003) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n02_03 · Cited by 32
“cannabinoid is an effective drug in the treatment of this movement disorder (Muller-Vahl et al. 1999, Muller-Vahl et al. 2002 ).”
BackgroundUpdates in Medical and Surgical Therapies for Tourette Syndrome
Malaty, I. A., & Akbar, U. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0458-4 · Cited by 33
Müller‐Vahl, K., Fremer, C., Beals, C. R., Ivkovic, J., Loft, H., & Schindler, C. (2021) · Pharmacopsychiatry · doi:10.1055/a-1675-3494 · Cited by 31
“However, this evidence is mainly based on data from open uncontrolled case series using different exocannabinoids, two small randomized, placebo-controlled studies using pure THC [7–11], and elevated cerebrospinal fluid levels of endocannabinoids in TS [35].”
InfluentialMedical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study
Anis, S., Zalomek, C., Korczyn, A. D., Rosenberg, A., Giladi, N., & Gurevich, T. (2022) · Behavioural Neurology · doi:10.1155/2022/5141773 · Cited by 31
“, using tetrahydrocannabinol (THC, dronabinol), have demonstrated safety and efficacy in the treatment of tics in patients with GTS [18, 19].”
BackgroundMethodResultInfluentialJakubovski, E., Pisarenko, A., Fremer, C., Haas, M., May, M., Schumacher, C., Schindler, C., Häckl, S., Dávila, L. A., Koch, A., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.575826 · Cited by 29
Update and recent progress in the neurobiology of Tourette syndrome
Szejko, N. (2022) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.11.003 · Cited by 28
Müller‐Vahl, K. (2024) · Pharmacopsychiatry · doi:10.1055/a-2256-0098 · Cited by 34
“In two small-scale studies including N = 12 (single dose of THC up to 10 mg) and N = 24 patients (up to 10 mg THC/day for 6 weeks), respectively, THC resulted in a significant improvement of tics [132, 133] with - out causing impairment in neuropsychological performance [134, 135].”
BackgroundCannabis sativa and dystonia secondary to Wilson's disease
Roca, M. C. U., Micheli, F. E., & Viotti, R. (2004) · Movement Disorders · doi:10.1002/mds.20268 · Cited by 27
Szejko, N., Fichna, J. P., Safranow, K., Dziuba, T., Żekanowski, C., & Janik, P. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00125 · Cited by 27
“The clinical efficacy of cannabis-based medicines (CBM) also supports the involvement of ECS (Müller-Vahl et al., 2002; Müller-Vahl et al., 2003).”
BackgroundRittiphairoj, T., Leslie, L., Oberste, J.-P., Yim, T. W., Tung, G. J., Bero, L. A., Riggs, P., Hutchison, K. E., Samet, J. M., & Li, T. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03819 · Cited by 29
Bloch, M. H., Landeros‐Weisenberger, A., Johnson, J. A., & Leckman, J. F. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.19080178 · Cited by 30
Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders
Efron, D., & Taylor, K. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20085430 · Cited by 38
Pichler, E. M., Kawohl, W., Seifritz, E., & Roser, P. (2018) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217418791455 · Cited by 24
Clinical Pharmacology of Nondopaminergic Drugs in Tourette Syndrome
Hartmann, A. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00011-1 · Cited by 23
Tourette’s disorder in children and adolescents
Greydanus, D. E., & Tullio, J. (2020) · Translational Pediatrics · doi:10.21037/tp.2019.09.11 · Cited by 27
“A variety of other agents remain under study and include the cannabinoid delta-9-tetrahydrocannabinol, ecopipam (D1 receptor antagonist), clonazepam (benzodiazepine/ anxiolytic), n-acetylcysteine (amino acid), omega-3 fatty acids, ningdong granule (complementary and alternative therapy), 5-Ling granule (a proprietary…”
BackgroundOikonomou, P., & Jost, W. H. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02529-x · Cited by 24
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome
Szejko, N., Jakubovski, E., Fremer, C., & Müller‐Vahl, K. (2019) · Medical Cannabis and Cannabinoids · doi:10.1159/000496355 · Cited by 19
Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence
Wright, S. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0003-4 · Cited by 22
“Dronabinol Tourette syndrome RCT crossover Muller-Vahl [37, 38]”
Cannabinoids in movement disorders
Kluger, B. M., Huang, A. P., & Miyasaki, J. M. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.08.014 · Cited by 19
Pain in Tourette Syndrome: A Comprehensive Review
Green, B., Waters, A., & Shahed, J. J. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0025 · Cited by 19
Developmental and Behavioral Disorders Grown Up: Tourette's Disorder
Zinner, S. H., & Coffey, B. J. (2009) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181bd7f3e · Cited by 17
Tic Suppression: The Medical Model
Wu, S. W., Harris, E., & Gilbert, D. L. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0015 · Cited by 16
Substance Abuse and Movement Disorders
Luciano, M. S., & Saunders-Pullman, R. J. (2009) · Current Drug Abuse Reviews · doi:10.2174/1874473710902030273 · Cited by 18
Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome: case report
Szejko, N., Jakubovski, E., Fremer, C., Kunert, K., & Müller‐Vahl, K. (2018) · European Journal of Medical Case Reports · doi:10.24911/ejmcr/2/11 · Cited by 16
Shahed, J. J. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.011 · Cited by 19
The differential effects of medicinal cannabis on mental health: A systematic review
de Bode, N., Kroon, E., Sznitman, S. R., & Cousijn, J. (2025) · Clinical Psychology Review · doi:10.1016/j.cpr.2025.102581 · Cited by 18
Ceci, C., Onori, M. P., Macrì, S., & Laviola, G. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9510-z · Cited by 16
El papel de los cannabinoides en los trastornos del neurodesarrollo de niños y adolescentes
de Freitas, F. D., Pimenta, S., Soares, S., Gonzaga, D., Matos, I. V., & Prior, C. (2022) · Revista de Neurología · doi:10.33588/rn.7507.2022123 · Cited by 27
“…favours CBD over the placebo, with all three participants with outcome data in the CBD group reporting a clinically significant behavior improvement Müller-Vahl et al (2003) [17] GTS Randomized, double-blind, placebocontrolled study of 24 patients (18-68 years); 6-weeks THC-gelatine capsules;…”
BackgroundAndrzejewski, K. L., Barbano, R. L., & Mink, J. W. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.06.001 · Cited by 14
Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?
Tibbo, P. G., McKee, K. A., Meyer, J. H., Crocker, C. E., Aitchison, K. J., Lam, R. W. M., & Crockford, D. N. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720945525 · Cited by 14
Gorberg, V., McCaffery, P. J. A., & Anavi‐Goffer, S. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15302 · Cited by 15
“, 2010), reduces motor tics in a small number of adult patients (Muller-Vahl et al., 2003) and in two case studies of adolescent patients (Hasan et al.”
BackgroundRefractory Gilles de la Tourette Syndrome—Many Pieces That Define the Puzzle
Szejko, N., Lombroso, A., Bloch, M. H., Landeros‐Weisenberger, A., & Leckman, J. F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.589511 · Cited by 16
Uso terapéutico de los cannabinoides
Durán, M., & Capellà, D. (2004) · Adicciones · doi:10.20882/adicciones.412 · Cited by 22
Serag, I., Elsakka, M. M., Moawad, M. H. E. D., Ali, H. T., Sarhan, K., Shayeb, S., Nadim, I., & Abouzid, M. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03710-9 · Cited by 17
“Their use for controlling tics has recently increased, with many trials and reports showing encouraging results [23–30].”
BackgroundResultMedical and Surgical Treatments of Tourette Syndrome
Shahed, J. J. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.01.006 · Cited by 13
An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms
Lenka, A., & Jankovic, J. J. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2382463 · Cited by 12
Possible Role of the Endocannabinoid System in Tourette Syndrome
Szejko, N., Jakubovski, E., & Müller‐Vahl, K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79895 · Cited by 13
“published results of a randomized, double-blind, placebo-controlled follow-up trial [49].”
BackgroundNicolini, H., Martínez‐Magaña, J. J., Mendoza, A. D. G., Velázquez, J. A. V., Camarena, B., Fleiz, C., Bustos-Gamiño, M. N., García, A. A., Lanzagorta, N., & Medina‐Mora, M. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.664228 · Cited by 11
Tourette Syndrome and Tic Disorders
Tochen, L. S., & Singer, H. S. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00048-9 · Cited by 11
In silico approaches for study the therapeutic potential of Cannabis sativa (Bhang) against HIV
Kajal, V., Boora, S., Wadhwa, S., Soniya, K., Yadav, S., Kaushik, S., & Kaushik, S. (2023) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-023-00697-z · Cited by 10
Roessner, V., Schoenefeld, K., Buse, J., Wanderer, S., & Rothenberger, A. (2012) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000176 · Cited by 12
Pharmacotherapy for Tourette Syndrome
Jurgen, B., & Greenberg, E. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.08.008 · Cited by 10
Cannabis and Cannabis Based Medicine Extracts: Additional Results
Russo, E. B. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n04_03 · Cited by 9
Singer, H. S., Mink, J. W., Gilbert, D. L., & Jankovic, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820552-5.00017-6 · Cited by 9
Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Setting
Barchel, D., Stolar, O. E., Ziv‐Baran, T., Gueta, I., Berkovitch, M., Kohn, E., & Schleider, L. B. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0112 · Cited by 10
Schneider, U., Seifert, J., Karst, M., Schlimme, J. E., Cimander, K. F., & Müller‐Vahl, K. (2005) · Der Nervenarzt · doi:10.1007/s00115-005-1888-7 · Cited by 10
Self-citationTourette Syndrome and Tic Disorders
Frey, J. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001595 · Cited by 10
Roessner, V., & Rothenberger, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_26 · Cited by 8
Cannabinoids for the Treatment of Movement Disorders
Catlow, B. J., & Sanchez‐Ramos, J. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0370-5 · Cited by 10
Pharmacologie du cannabis et synthèse des analyses des principaux comités d’experts
Amar1, M. B. (2004) · Drogues santé et société · doi:10.7202/008535ar · Cited by 20
Cannabis-Induced Extrapyramidalism in a Patient on Neuroleptic Treatment
Altable, C. R., Rodríguez‐Urrutia, A., & Martínez, M. I. C. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150235.37737.02 · Cited by 8
Müller‐Vahl, K., Pisarenko, A., Ringlstetter, R., Cimpianu, C.-L., Fremer, C., Weidinger, E., Jenz, E. B., Musil, R., Brunnauer, A., & Großhennig, A. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0114 · Cited by 7
Harnessing the advances of genetic engineering in microalgae for the production of cannabinoids
Bolaños−Martínez, O. C., Malla, A., Rosales‐Mendoza, S., & Vimolmangkang, S. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2022.2071672 · Cited by 9
A single-center real-life study on the use of medical cannabis in patients with dystonia
Anis, S., Faust‐Socher, A., Sverdlov, D., Lassman, S., Hezi, N., Anis, O., Leor, G., Korczyn, A. D., Giladi, N., & Gurevich, T. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1218300 · Cited by 7
Cannabinoid-Based Drugs: Potential Applications in Addiction and Other Mental Disorders
Don, W., & Piomelli, D. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150009 · Cited by 7
Cell–cell communication by Endocannabinoids during Immune Surveillance of the Central Nervous System
Ullrich, O., Schneider‐Stock, R., & Zipp, F. (2006) · Springer eBooks · doi:10.1007/400_015 · Cited by 7
Working to Reform Marijuana Laws
Horgan, J., & Walsh, M. (2003) · Cited by 6
Efron, D., Taylor, K., Chan, E. J., Payne, J. M., Prakash, C., Lee, K. J., Cranswick, N., Lin, P., & Eapen, V. (2025) · Cannabis and Cannabinoid Research · doi:10.1089/can.2024.0188 · Cited by 7
“Although the numbers were very small, these data are consistent with adult studies of MC in TS 20,21 and support the need for a fully powered randomized controlled trial to test the ef fi cacy of MC in the pediatric TS population.”
Mathews, C. A., & Stern, J. S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00246 · Cited by 6
“There are limited case reports and two controlled trials of Delta 9-tetrahydrocannabinol (THC; Muller-Vahl et al., 2002, 2003) which followed single dose studies.”
BackgroundLasch, F., Guizzaro, L., Dávila, L. A., Müller‐Vahl, K., & Koch, A. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2100 · Cited by 6
Therapeutic properties of cannabinoid drugs and marijuana in several disorders: A narrative review
Alvarado, R. N., Dirección General Adjunta de Políticas y Programas contra las Adicciones, C. N. C. L. A., Sánchez, R. M. D. C., Salcedo, V. V., Dirección General de Políticas y Programas contra las Adicciones, C. N. C. L. A., & Departamento de Investigación Clínica, I. N. D. P. R. D. L. F. M. (2017) · Salud Mental · doi:10.17711/sm.0185-3325.2017.014 · Cited by 6
“Müller-Vahl et al., 2003.1 To evaluate THC effectiveness in the treatment of tics in Tourette’s syndrome.”
BackgroundInfluentialCannabinoids in functional tic-like movements
Ganos, C., & Müller‐Vahl, K. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.09.027 · Cited by 6
Introduction: Cannabis: From Pariah to Prescription
Russo, E. B. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n03_01 · Cited by 8
“Kirsten Müller-Vahl has pioneered the use of cannabis and THC in Tourette syndrome, demonstrating a marked reduction in tic behavior and obsessive-compulsive preoccupation (Muller-Vahl et al. 2003; Müller-Vahl et al. 1999).”
de Barros, P. M. F., Farhat, L. C., Behling, E., Nasir, M., Landeros‐Weisenberger, A., & Bloch, M. H. (2024) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2024.10.011 · Cited by 10
Long-term use of cannabis-based medicines in two children with Tourette syndrome: a case report
Woerner, L.-K., Szejko, N., Fremer, C., Schmitt, S., & Müller‐Vahl, K. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1647969 · Cited by 6
The therapeutic use of cannabis and cannabinoids
Silva, J. P., & Carvalho, F. D. (2022) · Revista Española de Drogodependencias · doi:10.54108/10032 · Cited by 6
Medical Marijuana in Pediatric Neurological Disorders
Patel, A. D. (2015) · Journal of Child Neurology · doi:10.1177/0883073815589761 · Cited by 6
Nilles, C., Amorelli, G., Pringsheim, T. M., & Martino, D. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1764164 · Cited by 5
papel da Medicina de Família e Comunidade no uso medicinal de Cannabis
da Silva, R. C. F., & de Albuquerque, G. M. C. (2023) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc18(45)3632 · Cited by 11
Pharmacological treatment of Tourette’s syndrome: from the past to the future
Gong, H., Du, X., Su, A., & Du, Y.-W. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07172-2 · Cited by 5
“The following year, a further study by Müller-Vahl found that patients achieved efficacy after 3 weeks of treatment with THC, and even increased beyond 4 weeks [138].”
Endocannabinoids and Dopamine-Related Functions in the CNS
de Miguel, R., Ramos, J. A., Cebeira, M., Hernández, M., & Fernández‐Ruíz, J. (2005) · CRC Press eBooks · doi:10.1201/9781420023640.ch11 · Cited by 4
Hyperkinetic Movement Disorders
Hess, C. W., & Saunders-Pullman, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3375-0_34 · Cited by 4
Müller‐Vahl, K. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_17 · Cited by 4
Prise en charge thérapeutique des tics dans la maladie de Gilles de Tourette
Diallo, R., Welter, M., & Mallet, L. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)90412-9 · Cited by 4
Medical Cannabis and Psychiatric Disorders: Implications for Psychiatric Nurses
Groh, C. J. (2020) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390320945791 · Cited by 5
“The second study (Muller-Vahl et al., 2003) randomized 24 subjects to 6 weeks of dronabinol or placebo, with the first and last 10 days to titrate on and off the medication, respectively.”
BackgroundMouvements anormaux de l’enfant : nouveautés thérapeutiques
Roubertie, A., Leydet, J., Rivier, F., Humbertclaude, V. T., Cheminal, R., & Échenne, B. (2004) · Archives de Pédiatrie · doi:10.1016/j.arcped.2004.01.009 · Cited by 3
Singer, H. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0435-8.00070-6 · Cited by 3
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_465-1 · Cited by 3
Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome
Szejko, N., & Müller‐Vahl, K. (2022) · International review of movement disorders · doi:10.1016/bs.irmvd.2022.04.002 · Cited by 4
Liu, H., Wang, C., Zhang, H., & Rezaei, M. J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1447818 · Cited by 3
Case Report: Secondary bilateral parkinsonism and dystonia treated with dronabinol
Szejko, N., Burger, F., Sidoroff, V., & Wenning, G. K. (2020) · F1000Research · doi:10.12688/f1000research.26476.3 · Cited by 3
Roessner, V., & Rothenberger, A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_27 · Cited by 3
Zhang, M., Zhang, Y., Chen, Y., Cen, Z., Li, J., Li, S., Li, H., Wan, L., Xiao, X. H., & Long, Q. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106130 · Cited by 2
Raminelli, A. O., Simei, J. L. Q., Guimarães, F. S., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & Osório, F. L. (2025) · Cannabis and Cannabinoid Research · doi:10.1177/25785125251378242 · Cited by 2
Wülfing, F., Schmidt‐Wolf, G., Cremer-Schaeffer, P., Priebe, K., & Schoofs, N. (2024) · Psychiatrische Praxis · doi:10.1055/a-2296-1358 · Cited by 2
Cannabiskonsum und Cannabiskonsumstörungen
Hoch, E., & Preuss, U. W. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01722-5 · Cited by 3
The Use of Cannabis-Based Medicine in Selected Neurological Disorders
Szejko, N., Saramak, K., & Müller‐Vahl, K. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_564 · Cited by 2
Metadata
- Authors
- Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Heinrich Heine University Düsseldorf (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-04-15
- Volume
- 64
- Issue
- 4
- Pages
- 459-465
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1981252279
- Cited by
- 270
- References
- 29
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 13 · 2023: 17 · 2022: 27 · 2021: 15 · 2020: 20 · 2019: 15 · 2018: 12 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 6 · 2013: 5 · 2012: 10
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- delta-9-tetrahydrocannabinol, Tourette syndrome, tics, cannabis, tic reduction, drug safety, Tourette syndrome treatment
- MeSH terms
- Adolescent, Adult, Double-Blind Method, Drug Administration Schedule, Female, Tourette Syndrome, Humans, Male, Middle Aged, Personality Inventory, Placebos, Psychiatric Status Rating Scales, Receptors, Drug, Severity of Illness Index, Dronabinol, Treatment Outcome, Tics, Receptors, Cannabinoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.